Exponent (EXPO) Q1 2025 earnings summary

Executive summary

• Q1 2025 results exceeded expectations, with resilience despite a 5-6% technical FTE headwind and macroeconomic uncertainty; revenues were $145.5M, nearly flat year-over-year, driven by chemicals, transportation, and utilities, but offset by easing in consumer electronics.

• Net income declined 12% to $26.7M ($0.52/diluted share) from $30.1M ($0.59) year-over-year, impacted by higher operating expenses and a negative tax effect from share-based awards.

• Billable hours fell 4% to 376,000; technical FTEs decreased 4% to 966; utilization remained flat at 75%.

• Business mix is 60% reactive (mainly litigation/dispute-driven) and 40% proactive, with over 10,000 engagements for 2,000+ clients in 2024.

• Sequential headcount grew 2% due to lower turnover, with mid-70s utilization.

Financial highlights

• Q1 2025 total revenues were $145.5M, flat year-over-year; net revenues (before reimbursements) were $137.4M, also flat.

• Net income decreased to $26.7M ($0.52/diluted share) from $30.1M ($0.59/diluted share) in Q1 2024.

• EBITDA fell 6% to $37.5M (27.3% margin) from $40.1M (29.2% margin) year-over-year.

• Operating income rose 44.7% to $44.4M, driven by reduced corporate operating expenses.

• Cash and cash equivalents at quarter-end were $245.1M, down from $258.9M at the start of the year.

Outlook and guidance

• Q2 2025: Net revenues expected down low single digits year-over-year; EBITDA margin 26-27%.

• Full year 2025: Net revenues to grow low single digits; EBITDA margin 26.25-27%.

• Full-year utilization expected at 72-73% (vs. 73% in 2024); realized rate increase of 3-3.5%.

• Stock-based compensation for 2025 expected at $23.7-24.2M; other operating expenses $49.5-50.5M.

• G&A expenses for 2025 projected at $24.8-25.8M, including a $2M managers' meeting.